EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Clinical Pharmacokinetics and Pharmacodynamics of Voclosporin

Emaad Abdel-Kahaar, Frieder Keller iD

Clinical Pharmacokinetics · 2023-05 · 62 (5) · 693-703

DOI: 10.1007/s40262-023-01246-2 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Pharmacokinetics, online erschienen am 03.05.2023. Verfasst von Emaad Abdel-Kahaar und 1 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Experimental and Clinical Pharmacology, Toxicology and Pharmacology of Natural Products, University Hospital Ulm, Helmholtzstrasse 20, 8…. Hauptthemen laut MEDLINE: Cyclosporine, Immunosuppressive Agents. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Universität Ulm.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Voclosporin is an approved option for the long-term treatment of lupus nephritis. We aimed to provide a narrative review of the pharmacokinetics and pharmacodynamics of voclosporin. In addition, we derived values for pharmacokinetic and pharmacodynamic parameters by graphical analysis of published diagrams. Compared with cyclosporin, low-dose voclosporin is associated with a lower nephrotoxicity risk and, compared to tacrolimus, with a lower diabetes risk. After repetitive dosing of 23.7 mg twice daily and at target trough concentrations of 10-20 ng/mL, the dominant or effect-indicative half-life is estimated at 7 hours. Compared with the pharmacodynamics of cyclosporin, the potency of voclosporin is stronger, with a lower concentration CE50 of 50 ng/mL already producing the half-maximum immunosuppressive effect. The Hill coefficient can be predicted to be low at H = 1.3, indicating a concentration-dependent effect on the immune system. The corresponding effect bisection time of 10 hours allows for dosing every 12 hours. Accordingly, the trough concentration will be above the threshold concentration that produces 5% of the maximum effect of 5.2 ng/mL for immunosuppression but below both the predicted threshold of 30 ng/mL for nephrotoxicity and the predicted threshold of 40 ng/mL for new-onset diabetes. The pharmacokinetic and pharmacodynamic properties suggest the use of low-dose voclosporin combined with mycophenolate and low-dose glucocorticoids for immunosuppressive maintenance therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CyclosporineImmunosuppressive AgentsHumansTacrolimusGlucocorticoids

Substanzen

voclosporinCyclosporineImmunosuppressive AgentsTacrolimusGlucocorticoids

Autor:innen und Institutionen

  • Institute of Experimental and Clinical Pharmacology, Toxicology and Pharmacology of Natural Products, University Hospital Ulm, Helmholtzstrasse 20, 89081, Ulm, Germany.
  • Department of Pharmacology, Qena Faculty of Medicine, South Valley University, Qena, Egypt.
  • , Ulm, Germany.
  • Institute of Experimental and Clinical Pharmacology, Toxicology and Pharmacology of Natural Products, University Hospital Ulm, Helmholtzstrasse 20, 89081, Ulm, Germany. frieder.keller@uni-ulm.de.

ORCID-Profile: Frieder Keller

Förderung

  • Universität Ulm

Zitieren

APA

Abdel-Kahaar, E., & Keller, F. (2023). Clinical Pharmacokinetics and Pharmacodynamics of Voclosporin. Clinical Pharmacokinetics, 62(5), 693-703. https://doi.org/10.1007/s40262-023-01246-2

Vancouver

Abdel-Kahaar E, Keller F. Clinical Pharmacokinetics and Pharmacodynamics of Voclosporin. Clinical Pharmacokinetics. 2023;62(5):693-703. doi:10.1007/s40262-023-01246-2

BibTeX
@article{AbdelKahaar2023,
  author = {Abdel-Kahaar, Emaad and Keller, Frieder},
  title = {Clinical Pharmacokinetics and Pharmacodynamics of Voclosporin},
  journal = {Clinical Pharmacokinetics},
  year = {2023},
  volume = {62},
  number = {5},
  pages = {693--703},
  doi = {10.1007/s40262-023-01246-2}
}
Kostenlos starten →